Singular Health Group (ASX:SHG) 5-Year EBITDA Growth Rate: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:SHG Singular Health Group Ltd ASX:SHG
27 GF Score
Price A$0.19
GF Value A$0.11
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Singular Health Group 5-Year EBITDA Growth Rate?

Singular Health Group ASX:SHG 27 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates ASX:SHG with a GF Score™ of 27/100 and a GF Value™ of A$0.11 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Singular Health Group's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was 22.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Singular Health Group was 22.70% per year. The lowest was 22.60% per year. And the median was 22.65% per year.


Singular Health Group  (ASX:SHG) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Singular Health Group 5-Year EBITDA Growth Rate Related Terms


ASX:SHG vs VEEV, BTSG, HQY: 5-Year EBITDA Growth Rate Comparison

For the Health Information Services subindustry, Singular Health Group's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Singular Health Group 5-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Singular Health Group's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Singular Health Group's 5-Year EBITDA Growth Rate falls into.


ASX:SHG
27GF Score
Singular Health Group Ltd ASX:SHG
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Singular Health Group 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Singular Health Group (ASX:SHG) has a 5-Year EBITDA Growth Rate of 0.00% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Singular Health Group and its competitors.
Is Singular Health Group's 5-Year EBITDA Growth Rate too high?
Singular Health Group's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Singular Health Group has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Singular Health Group's 5-Year EBITDA Growth Rate compare to VEEV and BTSG?
Singular Health Group's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
A good 5-Year EBITDA Growth Rate depends on the Healthcare Providers & Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Singular Health Group and its competitors. Singular Health Group's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Singular Health Group stock overvalued right now?
Based on GuruFocus' analysis, Singular Health Group (ASX:SHG) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.11, compared to a current price of A$0.19 — trading 72.7% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Singular Health Group's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Singular Health Group (ASX:SHG), the current 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Singular Health Group (ASX:SHG) Overvalued in 2026?

Based on GuruFocus' analysis, Singular Health Group stock appears to be overvalued. The current stock price of A$0.19 is trading 72.7% above its estimated GF Value™ of A$0.11. GuruFocus considers Singular Health Group to be Significantly Overvalued.

Key valuation signals for ASX:SHG:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: A$0.11 vs. price of A$0.19 (72.7% above fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the ASX:SHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Singular Health Group Business Description

Address E3 and E4, 661 Newcastle Street, Leederville, WA, AUS, 6007
Singular Health Group Ltd provides medical software solutions. The company's business segment is the provision of Volume Rendering Platform (VRP) software, providing 3D printing services and 3D machine sales. It operates in one segment, which is the provision and development of medical technology within Australia.
27GF Score

Get the complete analysis for ASX:SHG

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.19
Price
A$0.11
GF Value